Table 2.

Multiple Linear Regression to Identify Predictors of Quality of Life at Follow-Up

Variable	PCS						MCS
	Adjusted for Initial PCS			Adjusted for Initial PCS and Other Predictors (n = 519)			Adjusted for Initial MCS			Adjusted for Initial MCS and Other Predictors (n = 519)
	Coefficient, β	SE	P	Coefficient, β	SE	P	Coefficient, β	SE	P	Coefficient, β	SE	P
Initial PCS or MCS	0.74	0.03	< .001	0.52	0.04	< .001	0.65	0.03	< .001	0.47	0.04	< .001
Demographicsa
Female sex	0.17	0.69	.807				−1.39	0.73	.055	−1.03	0.69	.134
Nonwhite race	−0.63	1.04	.544				−1.42	1.10	.201
Income < $30,000	−1.93	0.90	.032	−1.21	0.84	.150	−1.31	0.96	.173
Less than college degree	−0.36	0.72	.616				−1.00	0.74	.177
Not married	−0.25	0.89	.782				−0.09	0.94	.925
Age at study enrollment	−0.16	0.03	< .001	−0.21	0.03	< .001	−0.01	0.03	.631
Clinical characteristicsb
Years since diagnosis	−0.06	0.05	.237				0.004	0.05	.943
Recurrence in last 5 yearsc	0.51	0.73	.485				0.84	0.79	.288
Systemic treatment statusd
Received chemotherapy	−0.47	1.03	.651				−2.16	1.09	.049	−1.36	1.05	.195
Received biologic treatment	1.47	1.76	.404				0.07	1.87	.972	1.65	1.77	.353
Chemotherapy-biologic therapy interaction	0.14	1.18	.903				−2.21	1.25	.078	−1.03	1.20	.394
Ever had transplantation	−0.34	1.24	.783				−1.26	1.32	.339	0.49	1.30	.703
No systemic treatment ever
Comorbidity scoree	−0.30	0.10	.002	−0.25	0.09	.006	−0.23	0.09	.009	−0.11	0.09	.220
Lymphoma symptom scoref	0.68	0.47	.143				2.13	0.51	< .001	0.58	0.59	.324
Psychosocial statusg
Social Supporth	0.02	0.02	.356				0.06	0.02	.008	0.04	0.02	.096
IOC Negative Impacti	−0.80	0.54	.136	−3.05	0.53	< .001	−2.66	0.65	< .001	−3.70	0.78	< .001
IOC Positive Impactj	0.003	0.45	.994	0.0001	0.44	.999	−0.65	0.48	.175
Δ Social support	0.02	0.02	.340				0.03	0.02	.165
Δ IOC Negative Impact	−3.71	0.61	< .001	−5.21	0.60	< .001	−3.91	0.65	< .001	−4.88	0.67	< .001
Δ IOC Positive Impact	1.18	0.61	.052	1.49	0.59	.012	1.05	0.65	.104
Model-adjusted R2 P			.48			.59			.41			.50

Abbreviations: IOC, Impact of Cancer; MCS, Mental Component Score; PCS, Physical Component Score.

^aDemographic variables are from the 2005 survey.

^bClinical variables are from the 2005 survey (years since diagnosis, comorbidity, lymphoma symptom score, and systemic treatment status) and the follow-up 2010 survey (systemic treatment status and recurrence in last 5 years).

^cParticipants who reported having a recurrence of their lymphoma within the last 5 years or who have never been in remission.

^dMutually exclusive categories; participants reported receiving systemic treatment (ie, chemotherapy, biologic therapy such as rituximab, transplantation) at initial and/or follow-up survey.

^eSelf-Administered Comorbidity Questionnaire; possible score range, 0 to 42.

^fFunctional Assessment of Cancer Therapy–Lymphoma module; 15 items, possible score range, 0 to 60. Lower scores indicate greater symptoms.

^gPsychosocial variables are from the 2005 survey except for change variables.

^hMedical Outcomes Study Social Support total score; possible score range, 0 to 100; higher scores indicate higher support.

ⁱIOC Negative Summary score; possible score range, 1 to 5; higher scores indicate greater negative impacts.

^jIOC Positive Summary score; possible score range, 1 to 5; higher scores indicate greater positive impacts.